A major breakthrough in breast cancer treatment is bringing new hope to thousands of patients. The U.S. Food and Drug Administration (FDA) has approved Trodelvy as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).
The approval is especially important for Black women. They are diagnosed with triple-negative breast cancer at much higher rates than white women. They also tend to develop the disease at younger ages and often face poorer outcomes. As a result, the expanded use of Trodelvy could help improve treatment options for a community that has long needed better care.
FDA Approval of Trodelvy Expands Treatment Options for mTNBC
The approval, announced by Gilead Sciences on June 24, allows Trodelvy to be used earlier in treatment. Doctors can now prescribe it on its own for patients who cannot receive immunotherapy. It can also be combined with the immunotherapy drug Keytruda for patients whose tumors test positive for the PD-L1 protein through an FDA-approved test.
This expanded approval gives doctors more flexibility when choosing the best treatment plan. Instead of relying on one approach, they can now tailor care based on a patient’s overall health and the specific features of the cancer. That could lead to better outcomes for many people living with this aggressive disease.
What Is Metastatic Triple-Negative Breast Cancer?
Triple-negative breast cancer is one of the hardest forms of breast cancer to treat. Unlike many other breast cancers, it does not have estrogen receptors, progesterone receptors, or excess HER2 protein. These are the targets used by many standard breast cancer treatments.
When the cancer becomes metastatic, it has spread beyond the breast to other parts of the body, including the bones, lungs, liver, or brain. Because common hormone therapies and HER2-targeted drugs do not work against this type of cancer, patients have historically had fewer treatment options. The disease also tends to grow and spread more quickly.
How Trodelvy Targets Cancer Cells More Precisely
Trodelvy is a targeted therapy designed to deliver chemotherapy directly to cancer cells while reducing damage to healthy tissue. It works by attaching to a protein called Trop-2, which is found in high amounts on more than 90% of breast and lung cancer cells.
Once attached, the medicine releases chemotherapy directly inside the cancer cell. Some of the drug also spreads into nearby tumor tissue, helping destroy surrounding cancer cells. This targeted method allows the treatment to attack cancer more precisely than traditional chemotherapy.
Clinical Trials Show Strong Results for Trodelvy
The FDA based its decision on results from the Phase 3 ASCENT-03 and ASCENT-04/KEYNOTE-D19 clinical trials. The studies showed that Trodelvy-based treatments significantly improved outcomes for people with metastatic triple-negative breast cancer.
For patients who were not eligible for PD-L1-targeted immunotherapy, Trodelvy reduced the risk of disease progression or death by 38% compared with chemotherapy alone. Among patients with PD-L1-positive tumors, combining Trodelvy with Keytruda reduced that risk by 35% compared with Keytruda plus chemotherapy.
Researchers also explained that Keytruda helps the immune system recognize and attack cancer cells. Adding Trodelvy made that response even stronger, leading to longer periods before the disease worsened.
Why This Breakthrough Matters for Black Women
The FDA approval has been welcomed by breast cancer advocates who have long pushed for better treatment options. One of those voices is Ricki Fairley, co-founder and CEO of TOUCH, The Black Breast Cancer Alliance, and a survivor of triple-negative breast cancer.
Fairley said the approval offers new hope to patients who have historically had very few choices.
“For patients with metastatic TNBC, a new first-line treatment option offers optimism to a community with historically few choices.”
She also highlighted the impact on Black women.
“TNBC disproportionately affects younger women—many in the prime of their lives—and often leads to poorer outcomes. Because so many patients may never receive subsequent lines of therapy, the ability to start with a promising option like Trodelvy with or without Keytruda is critical.”
According to Fairley, Black women are diagnosed with triple-negative breast cancer about 2.3 times more often than white women. They also experience a 42% higher death rate from the disease. Those differences make advances like Trodelvy especially meaningful.
Trodelvy Continues to Gain Global Recognition
Following the positive trial results, the National Comprehensive Cancer Network now recommends Trodelvy, with or without Keytruda, as a Category 1 preferred first-line treatment for metastatic triple-negative breast cancer, regardless of PD-L1 status.
The treatment has already been used by more than 75,000 breast cancer patients across over 60 countries during the past six years. It also remains the only Trop-2-directed antibody-drug conjugate to show significant overall survival benefits in both later-stage metastatic triple-negative breast cancer and previously treated hormone receptor-positive, HER2-negative metastatic breast cancer.
For many patients, especially Black women facing higher risks, this FDA approval represents more than another medicine. It offers renewed hope that better treatment can lead to better outcomes and longer lives.
